Study of the Prevalence of Autistic Traits in Angelman Syndrome
NCT ID: NCT06337383
Last Updated: 2024-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
46 participants
OBSERVATIONAL
2022-03-15
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* which clinical variables differentiate AS patients with and without Autism Spectrum Disorder between genetics, epilepsy, pharmacotherapy, behavioural problems, parenting style and parents' perceived stress.
* which clinical variables differentiate parenting styles and levels of perceived stress.
Data from neuropsychological, speech therapy and physiotherapeutic assessments are collected during regular clinical follow-ups, regarding: cognitive development ("Bayely Scales of Infant Development-III", Cognitive Scale) and adaptive behaviour; Autism and Autism Spectrum Disorder ("Autism Diagnostic Observational Schedule-2"); parental stress and parenting styles; social-communicative skills; motor development.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Use of Eye Tracking to Study Social Perception Abnormalities in Children With Angelman Syndrome
NCT06737718
Natural History Study for Patients With Angelman Syndrome
NCT06229769
Clinical Characterization of Frequent Monogenic Forms of Neurodevelopmental Disorders
NCT04979182
Genotype-phenotype Correlations in Children and Adults With CTNNB1 Mutation
NCT04812119
Behavior, Neuropsychology, Neuroimage and Electrophysiology in Autistic Individuals With and Without CNVs
NCT01582256
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* chronological age between 4-15 years
Exclusion Criteria
* mental age lower than 12 months
* brain injury acquired in the peri- or postnatal period
4 Years
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IRCCS Eugenio Medea
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martina Baggio
Role: PRINCIPAL_INVESTIGATOR
Scientific Institute IRCCS E. Medea, Epilepsy Unit, Conegliano 31015, Italy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
I.R.C.C.S. "E.Medea"
Conegliano, Treviso, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12.2021 ANGELMAN
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.